Tremelimumab (CP-675,206), a Cytotoxic T Lymphocyte–Associated Antigen 4 Blocking Monoclonal Antibody in Clinical Development for Patients with Cancer

Tremelimumab (CP-675,206), a Cytotoxic T Lymphocyte–Associated Antigen 4 Blocking Monoclonal Antibody in Clinical Development for Patients with Cancer Antoni Ribas, Douglas C. Hanson, Dennis A. Noe, Robert Millham, Deborah J. Guyot, Steven H. Bernstein, Paul C. Canniff, Amarnath Sharma, Jesus Gomez-Navarro Oncologist 2007; 12: 873-883 Author Information and Disclosures Target Audience: Physicians who wish to advance their current knowledge of clinical cancer medicine in melanoma and cutaneous malignancies and are involved in providing patient care in a cancer care environment. Method of Physician Participation: Read course materials, complete course quiz and evaluation form (required). Learning Objectives After completing this course, the reader should be able to: Educate community oncologists about the promise of anti–CTLA-4 monoclonal antibodies for the treatment of advanced cancer. Suggest that CTLA-4 blockade overcomes barriers to effective immunotherapy for cancer. Describe the rational design and clinical development strategy taken with the CTLA-4 antagonist tremelimumab. The NIH/FAES designates this educational activity for a maximum of 1 AMA PRA Category 1 Credit™. Physicians should only claim credit commensurate with the extent of their participation in the activity.

CME Activity Information Accreditation CME Instructions For Credit Privacy Statement Hardware/Software Requirements Release Date: Aug. 2, 2007 Most Recent Review: Aug. 2, 2007* Most Recent Update: Aug. 2, 2007 Date Credit Expires: Aug. 2, 2009 Time to Complete: 1 hour Medium: Internet Online *Click here to learn more about our review process.

• Take this course